<DOC>
	<DOCNO>NCT01757431</DOCNO>
	<brief_summary>Protocol intend characterize overall safety tolerability eculizumab population .</brief_summary>
	<brief_title>The Safety Efficacy Eculizumab Japanese Patients With Atypical Hemolytic Uremic Syndrome ( aHUS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>1 . All patient diagnosis aHUS receiving eculizumab personal importation ( specific eligibility criterion apply ) Or , 2 . Patients current clinical manifestation aHUS meet follow criterion : 1 . Patient diagnosis aHUS without identified complement regulatory protein genetic abnormality anticomplement factor antibody know etiology hemolytic uremic syndrome ( HUS ) rule confirm Exclusion Criteria 2 . Patient ( legal guardian patient adult ) willing able give write informed consent assent ( verbal assent patient unable read write ) 3 . Patient least 1 month age body weight ≥5 kg 4 . Platelet count screen &lt; low limit normal ( LLN ) 5 . Signs symptoms hemolysis ( i.e. , lactate dehydrogenase ( LDH ) ≥ 1.5x upper limit normal ( ULN ) Hemoglobin ≤ LLN ) start current aHUS event 6 . Serum Creatinine ( SrCr ) level ≥ ULN screening ( patient require dialysis acute renal failure also eligible ) 7 . Female patient childbearing potential practicing effective , reliable medically approve contraceptive regimen entire duration study , include Followup Period . At time last followup visit , patient must agree continue use adequate contraception method 5 month follow discontinuation eculizumab treatment 8 . Able willing comply study procedure Shigatoxin produce E. coliHUS ( STECHUS ; shigatoxin and/or STEC positive ) History malignancy within 5 year screen Known human immunodeficiency virus ( HIV ) infection Identified drug exposurerelated HUS Infectionrelated HUS HUS relate bone marrow transplant ( BMT ) HUS relate vitamin B12 deficiency Known Systemic Lupus Erythematosus ( SLE ) antiphospholipid antibody positivity syndrome Chronic dialysis ( defined dialysis regular basis renal replacement therapy endstage renal disease ( ESRD ) ) Patients confirm diagnosis sepsis define positive blood culture within 7 day screen visit treat antibiotic organism sensitive Presence suspicion active untreated systemic bacterial infection , opinion Investigator confound accurate diagnosis aHUS impedes ability manage aHUS disease Pregnancy lactation Unresolved systemic meningococcal disease Any medical psychological condition , opinion investigator , could increase patient 's risk participate study confound outcome study Patients receive chronic intravenous immunoglobulin ( IVIG ) within 8 week unless unrelated medical condition ( e.g. , hypogammaglobulinemia ) chronic rituximab therapy within 12 week screen visit Patients receive immunosuppressive therapy steroid , calcineurin inhibitor ( mTOR ) , ( e.g. , cyclosporine tacrolimus ) exclude unless : [ 1 ] part establish posttransplant antirejection regimen , [ 2 ] patient confirm antiComplement Factor Antibodies require immunosuppressive therapy [ 3 ] steroid use condition aHUS ( e.g. , asthma ) Prior eculizumab use , hypersensitivity eculizumab , murine proteins one excipients Inclusion investigational intervention trial except study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>